Neurostimulation Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018

Neurostimulation Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018

Summary

GlobalData’s new report, “Neurostimulation Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018” provides key data, information and analysis on the global neurostimulation devices market. It outlines the market landscape and provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. The report also reviews the competitive landscape and technology offerings.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

- Key geographies covered are the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.
- Key segments covered are spinal cord stimulators, deep brain stimulators, sacral nerve stimulators, vagus nerve stimulators and cortical stimulators.
- Annualized market revenues data from 2004 to 2011, forecast to 2018, and company share data for 2011.
- Qualitative analysis of key market trends, market drivers, and restraints by category within the neurostimulation devices market.
- Information on the leading market players, the competitive landscape, and the leading pipeline products and technologies.
- Key players covered include Medtronic, St. Jude Medical, Boston Scientific Corporation and Cyberonics.

Reasons to buy

- Develop business strategies by understanding the trends and developments that are driving the neurostimulation devices market globally.
- Design and develop your product development, marketing and sales strategies.
- Develop market entry and market expansion strategies.
- Identify key players best positioned to take advantage of the emerging market opportunities.
- Exploit in-licensing and out-licensing opportunities by identifying the products most likely to ensure a robust return.
- What is the next big thing in the neurostimulation devices market landscape? Identify, understand and capitalize.
- Make more informed business decisions from the insightful and in-depth analysis of the global neurostimulation devices market and the factors shaping it. SHOW LESS READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 GlobalData Report Guidance
3 Disease Overview
3.1 Chronic Pain
3.1.1 Types of Chronic Pain Treated with Neurostimulation
3.1.2 Epidemiology
3.1.3 Treatment
3.2 Parkinson’s Disease
3.2.1 Epidemiology
3.2.2 Treatment
3.3 Epilepsy
3.3.1 Epidemiology
3.3.2 Treatment
4 Reimbursement for Neurostimulation Devices
4.1 Spinal Cord Stimulators
4.2 Deep Brain Stimulators
4.3 Sacral Nerve Stimulators
4.4 Vagus Nerve Stimulators
4.5 Reimbursement for Neurostimulators Developed as Humanitarian Use Devices
4.6 Centers for Medicare and Medicaid Services Payment Changes, 2011
4.6.1 Ambulatory Surgical Center Payment System Rates, 2011
4.6.2 US Medicare Hospital Outpatient Payment Rates, 2011
5 Device Overview - Neurostimulation Devices
5.1 Market Segmentation
5.1.1 Spinal Cord Stimulators
5.1.2 Deep Brain Stimulators
5.1.3 Sacral Nerve Stimulators
5.1.4 Vagus Nerve Stimulators
5.1.5 Cortical Stimulators
6 Neurostimulation Devices Market - Global Market Characterization
6.1 Neurostimulation Devices Market, Global, Revenue ($m), Historic, 2004-2011
6.2 Neurostimulation Devices Market, Global, Revenue ($m), Forecast, 2011-2018
6.3 Neurostimulation Devices, Market Dynamics
6.3.1 Market Drivers
6.3.2 Market Restraints
7 Neurostimulation Devices Market, Revenue ($m), by Country, 2004-2018
7.1 Neurostimulation Devices Market, The US, Revenue ($m), Historic, 2004-2011
7.2 Neurostimulation Devices Market, The US, Revenue ($m), Forecast, 2011-2018
7.3 Neurostimulation Devices Market, Canada, Revenue ($m), Historic, 2004-2011
7.4 Neurostimulation Devices Market, Canada, Revenue ($m), Forecast, 2011-2018
7.5 Neurostimulation Devices Market, The UK, Revenue ($m), Historic, 2004-2011
7.6 Neurostimulation Devices Market, The UK, Revenue ($m), Forecast, 2011-2018
7.7 Neurostimulation Devices Market, Germany, Revenue ($m), Historic, 2004-2011
7.8 Neurostimulation Devices Market, Germany, Revenue ($m), Forecast, 2011-2018
7.9 Neurostimulation Devices Market, France, Revenue ($m), Historic, 2004-2011
7.10 Neurostimulation Devices Market, France, Revenue ($m), Forecast, 2011-2018
7.11 Neurostimulation Devices Market, Italy, Revenue ($m), Historic, 2004-2011
7.12 Neurostimulation Devices Market, Italy, Revenue ($m), Forecast, 2011-2018
7.13 Neurostimulation Devices Market, Spain, Revenue ($m), Historic, 2004-2011
7.14 Neurostimulation Devices Market, Spain, Revenue ($m), Forecast, 2011-2018
7.15 Neurostimulation Devices Market, Japan, Revenue ($m), Historic, 2004-2011
7.16 Neurostimulation Devices Market, Japan, Revenue ($m), Forecast, 2011-2018
7.17 Neurostimulation Devices Market, China, Revenue ($m), Historic, 2004-2011
7.18 Neurostimulation Devices Market, China, Revenue ($m), Forecast, 2011-2018
7.19 Neurostimulation Devices Market, India, Revenue ($m), Historic, 2004-2011
7.20 Neurostimulation Devices Market, India, Revenue ($m), Forecast, 2011-2018
7.21 Neurostimulation Devices Market, Australia, Revenue ($m), Historic, 2004-2011
7.22 Neurostimulation Devices Market, Australia, Revenue ($m), Forecast, 2011-2018
7.23 Neurostimulation Devices Market, Brazil, Revenue ($m), Historic, 2004-2011
7.24 Neurostimulation Devices Market, Brazil, Revenue ($m), Forecast, 2011-2018
8 Global Neurostimulation Devices Market - Strategic Competitive Assessment
8.1 Neurostimulation Devices Market, Global, Company Share (%), 2011
8.2 Medtronic
8.2.1 Overview
8.2.2 Medtronic, Key Marketed Products
8.3 St Jude Medical
8.3.1 Overview
8.3.2 St Jude Medical, Marketed Products
8.4 Boston Scientific
8.4.1 Overview
8.4.2 Boston Scientific, Marketed Products
8.5 Cyberonics
8.5.1 Overview
8.5.2 Cyberonics, Key Marketed Products
9 Neurostimulation Devices Market - Pipeline Assessment
9.1 Spinal Cord Stimulators, Pipeline Products
9.1.1 Algostim Device
9.1.2 Genesis Neurostimulation System
9.1.3 Nevro Senza System
9.1.4 Next Generation Spinal Cord Stimulator System
9.1.5 Precision Plus Spinal Cord Stimulation System
9.1.6 PrimeADVANCED - Heart Failure
9.1.7 Subcutaneous Array of Implantable Neural Transponder System
9.2 Deep Brain Stimulators, Pipeline Products
9.2.1 Activa PC - Refractory Epilepsy
9.2.2 Brio Neurostimulator
9.2.3 Coordinated Reset-Capable Implant
9.2.4 Deep Brain Stimulation - Alzheimer’s Disease
9.2.5 Deep Brain Stimulation - Mild Cognitive Impairment
9.2.6 Deep Brain Stimulation System - Cachexia
9.2.7 Deep Brain Stimulation System - Obesity
9.2.8 Deep Brain Stimulation System - Post-Traumatic Stress Disorder
9.2.9 Deep Transcranial Magnetic Stimulation System - Alzheimer's Disease
9.2.10 Deep Transcranial Magnetic Stimulation System - Autism
9.2.11 Deep Transcranial Magnetic Stimulation System - Bipolar Disorder
9.3 Sacral Nerve Stimulators, Pipeline Products
9.3.1 Sacral Nerve Stimulation Device
9.3.2 SAINT System - Urinary Incontinence
9.3.3 Verv System - Overactive Bladder
9.4 Vagus Nerve Stimulators, Pipeline Products
9.4.1 Aspire New Parameters
9.4.2 CardioFit System
9.4.3 FitNes System - Alzheimer’s Disease
9.4.4 NEMOS - Epilepsy
9.5 Cortical Stimulators, Pipeline Products
9.5.1 Cortistim
9.6 Other Neurostimulation Devices in the Pipeline
10 Neurostimulation Devices Market - Deals Landscape
10.1 Neurostimulation Devices Market: Mergers and Acquisitions
10.1.1 Sorin Group Invests $7m in Enopace Biomedical
10.1.2 Otto Bock Healthcare Acquires Remaining 44.4% Joint Venture Stake in Neurostream Technologies from Victhom Human Bionics
10.1.3 Boston Scientific Sells Neurovascular Business Unit to Stryker
10.1.4 Vycor Medical Completes Acquisition of NovaVision
10.2 Global Neurostimulation Devices Market, Venture Capital Deals
10.2.1 Functional Neuromodulation Raises Additional $3m in Venture Financing
10.2.2 Nervomatrix Secures $3.5m in Series A Venture Financing
10.2.3 Cortec Secures $3.2m in Seed Financing
10.2.4 ImThera Medical Secures $4m in Series C Venture Financing
10.2.5 Phagenesis Secures $9.3m in Series B Venture Financing
10.2.6 Autonomic Technologies Secures $32m in Series C Venture Financing
10.2.7 SPR Therapeutics Secures $0.25m in Financing Round
10.2.8 Nexstim Secures Additional $2.8m in Venture Financing Round
10.2.9 BlueWind Medical Secures Seed Financing
10.2.10 Synapse Biomedical Secures $0.43m in Financing Round
10.2.11 EBS Technologies Secures $4.4m in Second Round of Financing
10.3 Global Neurostimulation Devices Market, Partnership Deals
10.3.1 GE Healthcare Enters into a Distribution Agreement with KC BioMedix
10.3.2 EndoStim Enters into an Agreement with Arizona State University
10.3.3 Ardiem Medical Enters into Licensing Agreement with Case Western Reserve University
11 Appendix
11.1 Definitions
11.1.1 Neurostimulation Devices
11.2 Acronyms
11.3 Sources
11.4 Research Methodology
11.4.1 Secondary Research
11.4.2 Primary Research
11.4.3 Models
11.4.4 Forecasts
11.4.5 Expert Panels
11.5 GlobalData Consulting
11.6 Contact Us
11.7 Disclaimer

1.1 List of Tables
Table 1: Ambulatory Surgical Center Medicare Payment for Spinal Cord Stimulation, 2010 vs. 2011
Table 2: Ambulatory Surgical Center Medicare Payment for Deep Brain Stimulation, 2010 vs. 2011
Table 3: Ambulatory Surgical Center Medicare Payment for Sacral Nerve Stimulation, 2010 vs. 2011
Table 4: Medicare Hospital Outpatient Payment for Spinal Cord Stimulation, 2010 vs. 2011
Table 5: Medicare Hospital Outpatient Payment for Sacral Nerve Stimulation, 2010 vs. 2011
Table 6: Medicare Hospital Outpatient Payment for Deep Brain Stimulation, 2010 vs. 2011
Table 7: Neurostimulation Devices Market, Global, Revenue ($m), 2004-2011
Table 8: Neurostimulation Devices Market, Global, Revenue ($m), 2011-2018
Table 9: Healthcare Costs vs. Health-related Quality of Life with Spinal Cord Stimulation and Conventional Medical Management
Table 10: Incremental Cost-effectiveness of Spinal Cord Stimulation Compared with Conventional Medical Management
Table 11: Cost Effectiveness, Post-vagus Nerve Stimulation Therapy vs. Pre-vagus Nerve Stimulation Therapy
Table 12: Example of Neurostimulation Products- through FDA’s Fast-track Program
Table 13: Example of Neurostimulation Products- through FDA’s Humanitarian Device Exemption Program
Table 14: Pipeline Products In Development for New Indications
Table 15: Neurostimulation Devices Market, The US, Revenue ($m), 2004-2011
Table 16: Neurostimulation Devices Market, The US, Revenue ($m), 2011-2018
Table 17: Neurostimulation Devices Market, Canada, Revenue ($m), 2004-2011
Table 18: Neurostimulation Devices Market, Canada, Revenue ($m), 2011-2018
Table 19: Neurostimulation Devices Market, The UK, Revenue ($m), 2004-2011
Table 20: Neurostimulation Devices Market, The UK, Revenue ($m), 2011-2018
Table 21: Neurostimulation Devices Market, Germany, Revenue ($m), 2004-2011
Table 22: Neurostimulation Devices Market, Germany, Revenue ($m), 2011-2018
Table 23: Neurostimulation Devices Market, France, Revenue ($m), 2004-2011
Table 24: Neurostimulation Devices Market, France, Revenue ($m), 2011-2018
Table 25: Neurostimulation Devices Market, Italy, Revenue ($m), 2004-2011
Table 26: Neurostimulation Devices Market, Italy, Revenue ($m), 2011-2018
Table 27: Neurostimulation Devices Market, Spain, Revenue ($m), 2004-2011
Table 28: Neurostimulation Devices Market, Spain, Revenue ($m), 2011-2018
Table 29: Neurostimulation Devices Market, Japan, Revenue ($m), 2004-2011
Table 30: Neurostimulation Devices Market, Japan, Revenue ($m), 2011-2018
Table 31: Neurostimulation Devices Market, China, Revenue ($m), 2004-2011
Table 32: Neurostimulation Devices Market, China, Revenue ($m), 2011-2018
Table 33: Neurostimulation Devices Market, India, Revenue ($m), 2004-2011
Table 34: Neurostimulation Devices Market, India, Revenue ($m), 2011-2018
Table 35: Neurostimulation Devices Market, Australia, Revenue ($m), 2004-2011
Table 36: Neurostimulation Devices Market, Australia, Revenue ($m), 2011-2018
Table 37: Neurostimulation Devices Market, Brazil, Revenue ($m), 2004-2011
Table 38: Neurostimulation Devices Market, Brazil, Revenue ($m), 2011-2018
Table 39: Neurostimulation Devices Market, Global, Company Revenue ($m), 2011
Table 40: Medtronic, Key Marketed Products-, Neurostimulation Devices
Table 41: Activa RC, PC and SC Series Neurostimulator, Features and Benefits
Table 42: Kinetra Neurostimulator, Features and Benefits
Table 43: Soletra Neurostimulator, Features and Benefits
Table 44: Restore Series Neurostimulator, Features and Benefits
Table 45: PrimeAdvanced Neurostimulator, Features and Benefits
Table 46: Itrel 3 neurostimulator, Features and Benefits
Table 47: External Trialing System, Features and Benefits
Table 48: St Jude Medical, Key Marketed Products-, Neurostimulation Devices
Table 49: Libra Family of Primary Cell IPGs, Features and Benefits
Table 50: Eon C Primary Cell IPGs, Features and Benefits
Table 51: Genesis Primary Cell IPG, Features and Benefits
Table 52: Rechargeable IPGs, Features and Benefits
Table 53: Boston Scientific, Key Marketed Products-, Neurostimulation Devices
Table 54: Precision Plus Spinal Cord Stimulation System, Features and Benefits
Table 55: Cyberonics, Key Marketed Products-, Neurostimulation Devices
Table 56: VNS Therapy Generator, Features and Benefits
Table 57: Spinal Cord Stimulators, Pipeline Products
Table 58: Algostim Device, Product Status
Table 59: Genesis Neurostimulation System - Chronic Angina, Product Status
Table 60: Nevro Senza System, Product Status
Table 61: Next Generation Spinal Cord Stimulator System, Product Status
Table 62: Precision Plus Spinal Cord Stimulation System, Product Status
Table 63: PrimeAdvanced - Heart Failure, Product Status
Table 64: Subcutaneous Array of Implantable Neural Transponder System - Chronic Pain, Product Status
Table 65: Deep Brain Stimulators, Pipeline Products
Table 66: Activa PC - Refractory Epilepsy, Product Status
Table 67: Brio Neurostimulator, Product Status
Table 68: CR-Capable Implant, Product Status
Table 69: Deep Brain Stimulation - Alzheimer’s Disease, Product Status
Table 70: Deep Brain Stimulation - Mild Cognitive Impairment, Product Status
Table 71: Deep Brain Stimulation - Cachexia, Product Status
Table 72: Deep Brain Stimulation - Obesity, Product Status
Table 73: Deep Brain Stimulation - Post-Traumatic Stress Disorder
Table 74: Deep TMS System - Alzheimer’s Disease, Product Status
Table 75: Deep Transcranial Magnetic Stimulation System - Autism, Product Status
Table 76: Deep Transcranial Magnetic Stimulation System - Bipolar Disorder, Product Status
Table 77: Sacral Nerve Stimulators, Pipeline Products
Table 78: Sacral Nerve Stimulation Device, Product Status
Table 79: SAINT System - Urinary Incontinence, Product Status
Table 80: Verv System - Overactive Bladder, Product Status
Table 81: Vagus Nerve Stimulators, Pipeline Products
Table 82: Aspire NP, Product Status
Table 83: CardioFit System, Product Status
Table 84: FitNes System - Alzheimer’s Disease, Product Status
Table 85: NEMOS - Epilepsy, Product Status
Table 86: Cortical Stimulators, Pipeline Products
Table 87: Cortistim, Product Status
Table 88: Other Neurostimulation Devices in the Pipeline
Table 89: Neurostimulation Devices Market, Mergers and Acquisitions, Global, 2010-2011
Table 90: Global Neurostimulation Devices Market, Venture Capital Deals
Table 91: Global Neurostimulation Devices Market, Partnership Deals

1.2 List of Figures
Figure 1: Neurostimulation Devices, Market Segmentation
Figure 2: Neurostimulation Devices Market, Global, Revenue ($m), 2004-2011
Figure 3: Neurostimulation Devices Market, Global, Revenue ($m), 2011-2018
Figure 4: Neurostimulation Devices, Regulatory Path for Pipeline Products, 2012
Figure 5: Neurostimulation Devices Market, The US, Revenue ($m), 2004-2011
Figure 6: Neurostimulation Devices Market, The US, Revenue ($m), 2011-2018
Figure 7: Neurostimulation Devices Market, Canada, Revenue ($m), 2004-2011
Figure 8: Neurostimulation Devices Market, Canada, Revenue ($m), 2011-2018
Figure 9: Neurostimulation Devices Market, The UK, Revenue ($m), 2004-2011
Figure 10: Neurostimulation Devices Market, The UK, Revenue ($m), 2011-2018
Figure 11: Neurostimulation Devices Market, Germany, Revenue ($m), 2004-2011
Figure 12: Neurostimulation Devices Market, Germany, Revenue ($m), 2011-2018
Figure 13: Neurostimulation Devices Market, France, Revenue ($m), 2004-2011
Figure 14: Neurostimulation Devices Market, France, Revenue ($m), 2011-2018
Figure 15: Neurostimulation Devices Market, Italy, Revenue ($m), 2004-2011
Figure 16: Neurostimulation Devices Market, Italy, Revenue ($m), 2011-2018
Figure 17: Neurostimulation Devices Market, Spain, Revenue ($m), 2004-2011
Figure 18: Neurostimulation Devices Market, Spain, Revenue ($m), 2011-2018
Figure 19: Neurostimulation Devices Market, Japan, Revenue ($m), 2004-2011
Figure 20: Neurostimulation Devices Market, Japan, Revenue ($m), 2011-2018
Figure 21: Neurostimulation Devices Market, China, Revenue ($m), 2004-2011
Figure 22: Neurostimulation Devices Market, China, Revenue ($m), 2011-2018
Figure 23: Neurostimulation Devices Market, India, Revenue ($m), 2004-2011
Figure 24: Neurostimulation Devices Market, India, Revenue ($m), 2011-2018
Figure 25: Neurostimulation Devices Market, Australia, Revenue ($m), 2004-2011
Figure 26: Neurostimulation Devices Market, Australia, Revenue ($m), 2011-2018
Figure 27: Neurostimulation Devices Market, Brazil, Revenue ($m), 2004-2011
Figure 28: Neurostimulation Devices Market, Brazil, Revenue ($m), 2011-2018
Figure 29: Neurostimulation Devices Market, Global, Company Share- (%), 2011
Figure 30: Global Neurostimulation Devices, Product Mapping
Figure 31: Neurostimulation Devices, Analysis of Pipeline Products by Clinical Stage of Development

Neurostimulation Devices Market Grows as the World Gets Older

Neurostimulation devices used to treat conditions such as Parkinson’s disease and chronic back pain are becoming more common as the world’s elderly population increases, according to a report by healthcare industry analysts GlobalData.

The new report* states that the value of the market was $2.3 billion in 2011, but will almost double by 2018 to reach $4.4 billion in 2018, climbing at a Compound Annual Growth Rate (CAGR) of 10%.

GlobalData largely attributes this growth to expanding patient pools for ailments typically associated with older people: Parkinson’s disease, overactive bladder, chronic pain, essential tremor and dystonia. These conditions cost national healthcare authorities around the world billions of dollars annually, making clinically proven and cost-effective neurostimulation therapy an attractive solution.

Successful treatment outcomes for people with these disorders have led to extensive further research. As a result, the market pipeline consists of traditional applications for neurostimulation therapy, as well as new and innovative ones.

In the US, the Food and Drug Administration’s (FDA) fast-tr.ack program, intended to facilitate progress and a quick review process, is encouraging companies to invest in the development of advanced neurostimulation devices designed to address serious conditions.

Furthermore, the Centers for Medicare and Medicaid Services (CMS) initiated a New Technology Add-on Payment (NTAP) program that provides payment incentives under Medicare’s inpatient prospective payment system. Beginning in 2001, the program reimburses up to 50% of the cost of the implementation of new technologies, further promoting innovation.

Included among the approved technologies under the NTAP program is bilateral Deep Brain Stimulators (DBS) for the treatment of Parkinson’s disease, and rechargeable implantable spinal cord neurostimulators, which are used for the treatment of chronic pain.

According to 2011 figures, Medtronic dominates the global neurostimulation devices market, with a huge 62% share and revenue of $1.4 billion. The firm holds such a strong position due to a number of factors, including 37 manufacturing sites around the world and a presence in the market for over 30 years. St. Jude Medical held the second largest portion with 15% of the market, with Boston Scientific not far behind with a 13% share.

* Neurostimulation Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018

This report provides key data, information and analysis on the global neurostimulation devices market. It also outlines the market landscape and provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.